Articles related to PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

Uncover the groundbreaking advancements in PNH treatment, from oral therapies to dual inhibition strategies, and their implications for patient outcomes.

This educational activity aims to meet the needs of the interprofessional team responsible for managing patients with PNH. Upon completion of this activity, participants will be able to demonstrate a comprehensive understanding of the pathophysiology of PNH and its implications, identify the prevalence of the disease and the unmet needs of patients, articulate the clinical indicators of successful PNH management and their significance, interpret guidelines and distinguish between the safety profiles of current and upcoming PNH therapeutics, and gain knowledge about emerging data on drug classes and mechanisms, including EVH, IVH, anemia, and adherence to pharmacological treatments for PNH.

Parallels and distinct features among paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are discussed against the background of thrombosis, complement activation via eculizumab, and potential complement diagnostic and therapeutic avenues.